Download PDF
Exp Clin Endocrinol Diabetes 2005; 113(4): 195-198
DOI: 10.1055/s-2005-837735
Article

J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Evaluation of a New Indicator Test for Sudomotor Function (Neuropad®) in the Diagnosis of Peripheral Neuropathy in Type 2 Diabetic Patients

N. Papanas1 , K. Papatheodorou1 , D. Christakidis2 , D. Papazoglou1 , G. Giassakis3 , H. Piperidou3 , C. Monastiriotis1 , E. Maltezos1
  • 1Second Department of Internal Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, Dragana, Alexandroupolis, Greece
  • 2Diabetic Department, University Hospital of Alexandroupolis, Dragana, Alexandroupolis, Greece
  • 3Department of Neurology, Democritus University of Thrace, University Hospital of Alexandroupolis, Dragana, Alexandroupolis, Greece
Further Information

Publication History

Received: May 1, 2004 First decision: June 28, 2004

Accepted: January 8, 2005

Publication Date:
13 May 2005 (online)

Also available at
    Permissions and Reprints

Abstract

Sudomotor neuropathy is associated with reduction of plantar sweating and contributes to the pathogenesis of diabetic foot ulcers. The aim of the present study was to evaluate the new indicator test for sudomotor function (Neuropad®) in the diagnosis of peripheral neuropathy among type 2 diabetic patients. This study included 104 type 2 diabetic patients (51 men) with a mean age of 64.2 ± 5.6 years and a mean diabetes duration of 12.8 ± 3.7 years. Peripheral neuropathy was diagnosed by means of the Diabetic Neuropathy Index (DNI). Sudomotor neuropathy was assessed by means of colour change in the indicator test. Peripheral neuropathy was diagnosed in 71 patients (68.3 %). Sudomotor neuropathy was diagnosed in 67 patients (94.4 %) with peripheral neuropathy and in 10 patients (30.3 %) without peripheral neuropathy (p = 0.0001). Compared with DNI, sensitivity of the indicator test for diagnosing peripheral neuropathy was 94.4 % and specificity was 69.7 %. Overall prevalence of neuropathy was higher using the indicator test (77 patients, 74.0 %) than using the DNI (71 patients, 68.3 %). Time until complete colour change of the indicator test was 23.8 ± 6.7 min in patients with peripheral neuropathy and 7.7 ± 1.2 min in patients without peripheral neuropathy (p = 0.001). Among patients with peripheral neuropathy, time until complete colour change of the indicator test was 14.2 ± 1.9 min in those with a DNI value between 2.5 and 4.5, while it was 32.8 ± 2.6 min in those with a DNI value between 5 and 8 (p = 0.003). Conclusions: Use of the new indicator test has a very high sensitivity in detection of diabetic peripheral neuropathy. Sudomotor dysfunction can be demonstrated in a considerable part of patients with normal clinical examination. Time until complete colour change of the indicator test is associated with severity of peripheral neuropathy.

Key words

Diabetes mellitus - diabetic peripheral neuropathy - diabetic foot - sudomotor dysfunction

References

  • 1 Ahroni J H, Boyko E J, Davignon D R, Pecoraro R E. The health and functional status of veterans with diabetes.  Diabetes Care. 1994;  4 318-321
    PubMedGoogle Scholar
  • 2 Bax G, Fagherazzi C, Piarulli F, Nicolucci A, Fedele D. Reproducibility of Michigan Neuropathy Screening Instrument (MNSI).  Diabetes Care. 1996;  19 904-905
    PubMedGoogle Scholar
  • 3 Boulton A JM, Gries F A, Jervell J. Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy.  Diabet Med. 1998;  15 508-514
    CrossrefPubMedGoogle Scholar
  • 4 Boulton A JM. Guidelines for diagnosis and outpatient management of diabetic peripheral neuropathy. European Association for the Study of Diabetes.  Neurodiab Diabetes Metab. 1998;  24 55-65
    PubMedGoogle Scholar
  • 5 Boulton A JM. The diabetic foot. Gries FA, Low PA, Cameron NE, Ziegler D Textbook of Diabetic Neuropathy. Stuttgart; Georg Thieme Verlag 2003: 295-305
    Google Scholar
  • 33 Braune H J, Horter C. Sympathetic skin response in diabetic neuropathy: a prospective clinical and neurophysiological trial on 100 patients.  J Neurol Sci. 1996;  138 120-124
    CrossrefPubMedGoogle Scholar
  • 6 Caccia M R, Dezuanni E, Salvaggio A, Osio M, Bevilacqua M, Norbiato G, Mangoni A. Sympathetic skin response versus maximum motor and sensory conduction velocity to detect subclinical neuropathy in non-insulin dependent diabetes.  Acta Neurol Belg. 1991;  91 213-222
    PubMedGoogle Scholar
  • 7 Duby J J, Campbell R K, Setter S M, White J R, Rasmussen K A. Diabetic neuropathy: an intensive review.  Am J Health Syst Pharm. 2004;  61 160-173
    PubMedGoogle Scholar
  • 8 Dyck P J, Davies J L, Litchy W J, O'Brien P C. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort.  Neurology. 1997;  49 229-239
    Google Scholar
  • 9 Fedele D, Comi G, Coscelli C, Cucinotta D, Feldman E L, Ghirlanda G, Greene D A, Negrin P, Santeusanio F. and the Italian Diabetic Neuropathy Committee . A multicenter study on the prevalence of diabetic neuropathy in Italy.  Diabetes Care. 1997;  20 836-843
    CrossrefPubMedGoogle Scholar
  • 10 Feldman E L, Stevens M J, Thomas P K, Brown M B, Canal N, Greene D A. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy.  Diabetes Care. 1994;  17 1281-1289
    CrossrefPubMedGoogle Scholar
  • 11 Forrest K YZ, Maser R E, Pambianco G, Becker D J, Orchard T J. Hypertension as a risk factor for diabetic neuropathy.  Diabetes. 1997;  46 665-670
    PubMedGoogle Scholar
  • 12 Hoeldtke R D, Bryner K D, Horvath G G, Phares R W, Broy L F, Hobbs G R. Redistribution of sudomotor responses is an early sign of sympathetic dysfunction in type 1 diabetes.  Diabetes. 2001;  50 436-443
    PubMedGoogle Scholar
  • 13 Jude E B, Boulton A JM. End-stage complications of diabetic neuropathy.  Diabetes Rev. 1999;  7 395-410
    PubMedGoogle Scholar
  • 14 Kennedy W R, Navarro X. Sympathetic sudomotor function in diabetic neuropathy.  Arch Neurol. 1989;  46 1182-1186
    CrossrefPubMedGoogle Scholar
  • 15 La Cava E C. Your nerves. Neuropathy affects more than 50 percent of people with diabetes. Here's what you can do to prevent it.  Diabetes Forecast. 2002;  55 67-69
    PubMedGoogle Scholar
  • 16 Litzelman D K, Marriott D J, Vinicor F. Independent physiological predictors of foot lesion in patients with NIDDM.  Diabetes Care. 1997;  20 1273-1278
    CrossrefPubMedGoogle Scholar
  • 17 Low P A. Sudomotor function. Gries FA, Low PA, Cameron NE, Ziegler D Textbook of Diabetic Neuropathy. Stuttgart; Georg Thieme Verlag 2003: 274-278
    Google Scholar
  • 18 Maser R E, Steenkiste A R, Dorman J S, Nielsen V K, Bass E B, Manjoo Q, Drash A L, Becker D J, Kuller L H, Greene D A. Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh Epidemiology of Diabetes Complications Study.  Diabetes. 1989;  38 1456-1461
    CrossrefPubMedGoogle Scholar
  • 19 Mason J, O'Keeffe C, Hutchinson A, McIntosh A, Young R, Booth A. A systematic review of foot ulcer prevention in patients with type 2 diabetes. 1: Prevention.  Diabet Med. 1999;  16 801-812
    CrossrefPubMedGoogle Scholar
  • 20 Perkins B A, Bril V. Diabetic neuropathy: a review emphasizing diagnostic methods.  Clin Neurophysiol. 2003;  114 1167-1175
    CrossrefPubMedGoogle Scholar
  • 21 Petit Jr W A, Upender R P. Medical evaluation and treatment of diabetic peripheral neuropathy.  Clin Podiatr Med Surg. 2003;  20 671-688
    PubMedGoogle Scholar
  • 22 Pirart J. Diabetes Mellitus and its degenerative complications: A prospective study of 4400 patients observed between 1947 and 1973.  Diabetes Care. 1978 a;  1 168-188
    PubMedGoogle Scholar
  • 23 Pirart J. Diabetes Mellitus and its degenerative complications: A prospective study of 4400 patients observed between 1947 and 1973.  Diabetes Care. 1978 b;  1 252-263
    PubMedGoogle Scholar
  • 24 Pittenger G, Vinik A. Nerve growth factor and diabetic neuropathy.  Exp Diabet Res. 2003;  4 271-285
    PubMedGoogle Scholar
  • 25 Podwall D, Gooch C. Diabetic neuropathy: clinical features, etiology, and therapy.  Curr Neurol Neurosci Rep. 2004;  4 55-61
    PubMedGoogle Scholar
  • 26 Reiber G E, Vileikyte L, Boyko E J, del Aguila M, Smith D G, Lavery L A, Boulton A JM. Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings.  Diabetes Care. 1999;  22 157-162
    CrossrefPubMedGoogle Scholar
  • 27 Shimada H, Kihara M, Kosaka S, Ikeda H, Kawabata K, Tsutada T, Miki T. Comparison of SSR and QSART in early diabetic neuropathy: value of length-dependent pattern in QSART.  Auton Neurosci. 2001;  92 72-75
    CrossrefPubMedGoogle Scholar
  • 28 The DCCT Research Group . Factors in development of diabetic neuropathy. Baseline analysis of neuropathy in feasibility phase of Diabetes Control and Complications Trial (DCCT).  Diabetes. 1988;  37 476-481
    PubMedGoogle Scholar
  • 29 Vinik A I, Maser R E, Mitchell B D, Freeman R. Diabetic autonomic neuropathy: Technical review.  Diabetes Care. 2003;  26 1553-1579
    CrossrefPubMedGoogle Scholar
  • 30 Young M J, Boulton A JM, MacLeod A F, Williams D RR, Sonksen P H. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population.  Diabetologia. 1993;  36 150-154
    CrossrefPubMedGoogle Scholar
  • 31 Zick R, Schäper T, Deeters U. Periphere diabetische Neuropathie. Die Schweißsekretion am Fuß messen.  Klinikarzt. 2003;  32 192-194
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Ziegler D, Cicmir I, Wiefels K, Berger H, Gries A. Peripheral and autonomic nerve function in long-term insulin-dependent diabetes.  Diabetes Res. 1987;  4 9-14
    PubMedGoogle Scholar

Dr. N. Papanas

Ethnikis Antistasis 44

Alexandroupolis 68100

Greece

Phone: + 302551084972

Fax: + 30 25 51 07 47 23

Email: papanasnikos@yahoo.gr

      >